Cargando…
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with a better selection of recruited patients. With the overall goal of creating a roadmap t...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468728/ https://www.ncbi.nlm.nih.gov/pubmed/30813545 http://dx.doi.org/10.3390/cells8030200 |
_version_ | 1783411500347555840 |
---|---|
author | Bagnoli, Marina Shi, Ting Yan Gourley, Charlie Speiser, Paul Reuss, Alexander Nijman, Hans W. Creutzberg, Carien L. Scholl, Suzy Negrouk, Anastassia Brady, Mark F. Hasegawa, Kosei Oda, Katsutoshi McNeish, Iain A. Kohn, Elise C. Oza, Amit M. MacKay, Helen Millan, David Bennett, Katherine Scott, Clare Mezzanzanica, Delia |
author_facet | Bagnoli, Marina Shi, Ting Yan Gourley, Charlie Speiser, Paul Reuss, Alexander Nijman, Hans W. Creutzberg, Carien L. Scholl, Suzy Negrouk, Anastassia Brady, Mark F. Hasegawa, Kosei Oda, Katsutoshi McNeish, Iain A. Kohn, Elise C. Oza, Amit M. MacKay, Helen Millan, David Bennett, Katherine Scott, Clare Mezzanzanica, Delia |
author_sort | Bagnoli, Marina |
collection | PubMed |
description | In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with a better selection of recruited patients. With the overall goal of creating a roadmap to improve translational design for future gynecological cancer trials and of defining translational goals, a main discussion was held during a brainstorming day of the Gynecologic Cancer InterGroup (GCIG) Translational Research Committee and overall conclusions are here reported. A particular emphasis was dedicated to the new frontier of the immunoprofiling of gynecological cancers. The discussion pointed out that to maximize patients’ benefit, translational studies should be integral to clinical trial design with standardization and optimization of procedures including a harmonization program of Standard Operating Procedures. Pathology-reviewed sample collection should be mandatory and ensured by dedicated funding. Biomarker validation and development should be made public and transparent to ensure rapid progresses with positive outcomes for patients. Guidelines/templates for patients’ informed consent are needed. Importantly for the public, recognized goals are to increase the involvement of advocates and to improve the reporting of translational data in a forum accessible to patients. |
format | Online Article Text |
id | pubmed-6468728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64687282019-04-23 Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions Bagnoli, Marina Shi, Ting Yan Gourley, Charlie Speiser, Paul Reuss, Alexander Nijman, Hans W. Creutzberg, Carien L. Scholl, Suzy Negrouk, Anastassia Brady, Mark F. Hasegawa, Kosei Oda, Katsutoshi McNeish, Iain A. Kohn, Elise C. Oza, Amit M. MacKay, Helen Millan, David Bennett, Katherine Scott, Clare Mezzanzanica, Delia Cells Perspective In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with a better selection of recruited patients. With the overall goal of creating a roadmap to improve translational design for future gynecological cancer trials and of defining translational goals, a main discussion was held during a brainstorming day of the Gynecologic Cancer InterGroup (GCIG) Translational Research Committee and overall conclusions are here reported. A particular emphasis was dedicated to the new frontier of the immunoprofiling of gynecological cancers. The discussion pointed out that to maximize patients’ benefit, translational studies should be integral to clinical trial design with standardization and optimization of procedures including a harmonization program of Standard Operating Procedures. Pathology-reviewed sample collection should be mandatory and ensured by dedicated funding. Biomarker validation and development should be made public and transparent to ensure rapid progresses with positive outcomes for patients. Guidelines/templates for patients’ informed consent are needed. Importantly for the public, recognized goals are to increase the involvement of advocates and to improve the reporting of translational data in a forum accessible to patients. MDPI 2019-02-26 /pmc/articles/PMC6468728/ /pubmed/30813545 http://dx.doi.org/10.3390/cells8030200 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Bagnoli, Marina Shi, Ting Yan Gourley, Charlie Speiser, Paul Reuss, Alexander Nijman, Hans W. Creutzberg, Carien L. Scholl, Suzy Negrouk, Anastassia Brady, Mark F. Hasegawa, Kosei Oda, Katsutoshi McNeish, Iain A. Kohn, Elise C. Oza, Amit M. MacKay, Helen Millan, David Bennett, Katherine Scott, Clare Mezzanzanica, Delia Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions |
title | Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions |
title_full | Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions |
title_fullStr | Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions |
title_full_unstemmed | Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions |
title_short | Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions |
title_sort | gynecological cancers translational, research implementation, and harmonization: gynecologic cancer intergroup consensus and still open questions |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468728/ https://www.ncbi.nlm.nih.gov/pubmed/30813545 http://dx.doi.org/10.3390/cells8030200 |
work_keys_str_mv | AT bagnolimarina gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT shitingyan gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT gourleycharlie gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT speiserpaul gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT reussalexander gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT nijmanhansw gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT creutzbergcarienl gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT schollsuzy gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT negroukanastassia gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT bradymarkf gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT hasegawakosei gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT odakatsutoshi gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT mcneishiaina gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT kohnelisec gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT ozaamitm gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT mackayhelen gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT millandavid gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT bennettkatherine gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT scottclare gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions AT mezzanzanicadelia gynecologicalcancerstranslationalresearchimplementationandharmonizationgynecologiccancerintergroupconsensusandstillopenquestions |